Clinical Trials

Find a Trial

Trial Summary

Protocol No.A081105
StatusOPEN TO ACCRUAL
Principal InvestigatorJalal, Shadia
ScopeNational
PhasePhase III
Age GroupAdult
TitleRANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF ERLOTINIB OR PLACEBO IN PATIENTS WITH COMPLETELY RESECTED EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)
DescriptionThis randomized phase III trial studies how well erlotinib hydrochloride compared to placebo works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Key EligibilityIn order to be eligible to take part in this trial, patients must meet the following criteria:
  • Completely resected stage IB (>= 4 cm), II or IIIA non-squamous NSCLC with negative margins
  • Previously registered to A151216, with the result of lung cancer harboring an EGFR exon 19 deletion or L858R mutation
For a full list of participation criteria, please visit ClinicalTrials.gov.
Applicable Disease SitesLung Cancer, Non-Small Cell
Participating InstitutionsIndiana University (IU)
  • Eskenazi Hospital
  • Indiana University Hospital / IU Simon Cancer Center
Roudebush VA Medical Center
    Treatment TypeTreatment